Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt

Zhiwei Xu1, Ju Mei1, Yan Tan2

  • 1Department of Cardiothoracic Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China.

Insights

Baicalin combined with cisplatin (DDP) shows synergistic effects in inhibiting lung cancer cell proliferation and invasion, even in DDP-resistant cells. This combination downregulates MARK2 and p-Akt, offering a potential strategy to overcome cisplatin resistance.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cisplatin (DDP) resistance is a significant challenge in lung cancer treatment.
  • Baicalin, a flavone glycoside, has potential therapeutic properties, but its role in DDP resistance is not well understood.
  • Investigating novel therapeutic strategies to overcome DDP resistance in lung cancer is crucial.

Purpose of the Study:

  • To investigate the combined effects of baicalin and DDP on human lung cancer cell proliferation and invasion.
  • To explore the underlying molecular mechanisms, focusing on MARK2 and Akt signaling pathways.
  • To determine if baicalin can overcome DDP resistance in lung cancer.

Main Methods:

  • Cell proliferation was assessed using MTT assays in A549 and DDP-resistant A549/DDP cells.
  • Tumor cell invasion was evaluated using Transwell invasion assays.
  • mRNA and protein expression levels of MARK2, p-Akt, and Akt were analyzed by qPCR and Western blot, respectively.
  • The probability sum method was used to determine drug combination effects.

Main Results:

  • Baicalin and DDP inhibited proliferation in a dose-dependent manner.
  • The combination of baicalin and DDP demonstrated synergistic effects on inhibiting proliferation and invasion in both sensitive and resistant lung cancer cells at specific concentrations and incubation times.
  • A549/DDP cells exhibited higher MARK2 and p-Akt expression; baicalin treatment dose-dependently decreased these markers.

Conclusions:

  • Baicalin and DDP exhibit synergistic activity in inhibiting lung cancer cell proliferation and invasion, irrespective of DDP resistance.
  • The observed chemosensitization is associated with the downregulation of MARK2 and phosphorylated Akt (p-Akt) signaling.
  • This combination therapy holds promise for overcoming DDP resistance in lung cancer.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K